Introduction
============

Breast cancer is the most diagnosed female cancer and the fifth leading cause of cancer death, and the mortality rate is 70,700 patients every year in China.[@b1-cmar-11-1473] The incidence and mortality of this cancer in women is increasing in recent years.[@b1-cmar-11-1473] Classical therapeutic strategy for this disease in clinic is combining the loco-regional therapy (surgery and radiation) with subsequent adjuvant systemic therapy.[@b2-cmar-11-1473]--[@b4-cmar-11-1473] However, as a highly heterogeneous disease, the therapeutic effect of breast cancer is determined by various classical clinical phenotypes (age at diagnosis, tumor size, stage of tumor, lymph node invasiveness, etc.) as well as intrinsic molecular subtypes (triple negative, human epidermal growth factor receptor 2 \[HER2\]-enriched, luminal A and luminal B subtypes).[@b2-cmar-11-1473],[@b5-cmar-11-1473] Besides, in the era of personalized medicine, genetic factors get increasing attention, which are considered as the most important aspects in tumor initiation, progression, prognosis, and drug resistance.[@b4-cmar-11-1473],[@b6-cmar-11-1473] Therefore, accurate molecular diagnosis of specific biomarkers that can respond to and monitor the therapeutic effect of breast cancer is essential.

As a major component of PI3K/AKT/mTOR signaling pathway, the activation of phosphatidylinositol-3 kinases (PI3K) which interacts with transmembrane tyrosine-kinase growth factor receptors subsequently activates AKT, mTOR, MAPK signaling pathways, and plays essential roles in multiple cellular processes including translation regulation, protein synthesis, cell metabolism, autophagy, cell adhesion, and apoptosis.[@b7-cmar-11-1473],[@b8-cmar-11-1473] Numerous studies illustrated that hyperactivation of PI3K signaling intimately was associated with pathogenesis and progression of various types of cancers.[@b9-cmar-11-1473]--[@b13-cmar-11-1473] There are two most important events that could constitutively activate the PI3K signaling pathway -- loss of the function of tumor suppressor phosphate and tension homology deleted on chromosome ten (PTEN) and activation mutations in p110α catalytic subunit which encoded by the *PIK3CA* gene.[@b8-cmar-11-1473],[@b14-cmar-11-1473] Between them, *PIK3CA* is one of the most prevalent mutated genes in breast cancer even though its mutation frequency varies among different investigations.[@b15-cmar-11-1473]--[@b19-cmar-11-1473] According to the Catalogue of Somatic Mutations in Cancer Database (COSMIC, <https://www.sanger.ac.uk>), \>90% of the *PIK3CA* mutations are located in the helical (exon 9) or kinase (exon 20) domains, including the hotspot mutations E542K, E545K in exon 9 and H1047R, H1047L in exon 20.

Therefore, multiple studies have been performed to investigate the relationship between *PIK3CA* mutations and clinicopathological features, prognostic value, or therapeutic relevance of breast cancer in different countries and races.[@b15-cmar-11-1473],[@b20-cmar-11-1473]--[@b22-cmar-11-1473] However, the results are controversial among these different studies even those from the same country. For example, in two investigations in the patients from Italy, Buttitta et al[@b23-cmar-11-1473] showed that *PIK3CA* mutations were associated with HER2-negative clinicopathological subtype, and in contrast, no association was determined by Barbareschi et al.[@b24-cmar-11-1473] Harlé et al[@b25-cmar-11-1473] attempted to correlate the *PIK3CA* mutations with low-grade tumors in breast cancer patients from Nancy, France, while by investigating the patients from Saint-Cloud, France, Cizkova et al[@b26-cmar-11-1473] believed that there were correlations between *PIK3CA* mutations and estrogen receptor (ER)-positive, progesterone receptor (PR)-positive, HER2 negative, low tumor grade or small tumor size. Considering the small sample sizes, population-related peculiarities of patients, and different methods used for detection of the mutations, these phenomena might demonstrate that it is crucially important to analyze carefully these factors in more areas including a larger population with a unique method. The outcomes would help us to deeply understand breast cancer and offer us specific and predictive biomarkers to be used for breast cancer diagnosis and treatment.

In this study, we investigated the frequency, distribution, bias, and burden of *PIK3CA* mutations in 494 breast cancer patients from a single center located in Central China and explored their associations with clinicopathological features and disease prognosis. These data will expand the knowledge of *PIK3CA* mutations related to breast cancer, which can be further used to provide precision medicine strategies to the breast cancer patients in Central China.

Materials and methods
=====================

Patients
--------

The study was conducted in accordance with the Declaration of Helsinki. After obtaining written informed consent from all the patients and approval of the Ethics Committee of the First Affiliated Hospital of USTC, 537 formalin-fixed, paraffin-embedded (FFPE) primary breast tumor tissue samples were collected at the Department of Pathology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China from 2010 to 2017. Ultimately, 494 samples were eligible for our analysis and the clinical characteristics of these patients are summarized in [Table S1](#SD3-cmar-11-1473){ref-type="supplementary-material"}. All the samples were obtained from female patients who did not receive preoperative treatment. Based on the American Joint Committee on Cancer TNM system (2010),[@b27-cmar-11-1473] the pathological diagnosis of each sample was made by at least three pathologists. The Nottingham Prognostic Index (NPI)[@b28-cmar-11-1473] was calculated to determine the prognosis of the patients after surgery using the following formula: NPI =0.2×tumor size (cm)+ grade (1--3)+ lymph node status (1--3). Progression-free survival (PFS) was defined as the time span between surgery date and the first relapse time of tumor, second primary tumor, death, or last follow-up.[@b29-cmar-11-1473] Among 494 patients, 303 PFS and overall survival (OS) data were collected in which 28 of them had relapsed tumor or second primary tumor and 46 patients died. The follow-up period was from 5 to 97 months with a median time of 35 months.

Molecular subtypes of breast cancer
-----------------------------------

ER, PR, and HER2 statuses were determined by immunohistochemical (IHC) staining. ER or PR was regarded as positive when \>1% of tumor cells were stained based on the St. Gallen International Expert Consensus.[@b30-cmar-11-1473] HER2 was considered positive when complete or intense membrane staining was determined in \>30% of tumor cells. The subtypes of samples were classified using anatomopathological classification according to St. Gallen International Expert Consensus.[@b30-cmar-11-1473] The expression of Ki67 -- a cellular marker for proliferation -- was also examined by IHC in all patients.

DNA preparation and targeted next generation sequencing
-------------------------------------------------------

Tumor content of \>50% was qualified through H&E staining and selected for DNA extraction. Genomic DNA was extracted from one 10 µm section using the GeneRead DNA FFPE Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The quantity and quality of extracted DNA were determined using Nanodrop spectrophotometer 2000 (Thermo Fisher Scientific, MA, USA) and Qubit 3.0 (Life Technologies, Carlsbad, CA, USA).

Genetic variants of 24 samples were screened with TruSeq Amplicon Cancer Panel (Illumina, San Diego, CA, USA) using the NextSeq 500 sequencing system (Illumina). Mutations in 212 amplicons from 48 genes were examined in these samples, including *BRAF*, *KRAS*, *EGFR*, *TP53*, *NRAS*, *ALK*, *IDH1*, *FGFR*, *PTEN*, *RB*, *ATM*, *PIK3CA*, and other important cancer-related genes. Among them, the total 20 exons of *PIK3CA* were targeted.

After sequencing, mapping, and alignment, single nucleotide variants (SNVs) and indels were called and annotated based on the method described by The Cancer Genome Altas.[@b31-cmar-11-1473] Variants with insufficient coverage (minimum depth of coverage \<8) and low variant allele frequency (\<0.03) were filtered out.

PCR amplification of the *PIK3CA* exon 9 and exon 20 fragments
--------------------------------------------------------------

The exon 9 and exon 20 of *PIK3CA* gene were amplified using the following primers: exon 9 forward 5′-TGTAAAACGACG-GCCAGTCAGAGTAACAGACTAGCTAGAGACAATG-3′, exon 9 reverse 5′-CAGGAAACAGCTATGACCAATCTC-CATTTTAGCACTTACCTGTGAC-3′, and exon 20 forward 5′-TGAGCAAGAGGCTTTGGAGTAT-3′, exon 20 reverse 5′-CCTATGCAATCGGTCTTTGC-3′. The PCR was performed in a 20 µL reaction system using FastStart Essential DNA Green Master Kit (Roche, Mannheim, Germany) with 1 µL gDNA, 1 µL forward primer (10 nmol/mL), 1 µL reverse primer (10 nmol/mL), and 10 µL FastStart Essential DNA Green Master. The PCR was carried out on a LightCycler 96 Real-Time PCR System (Roche) under the following conditions: initial denaturation at 95°C for 5 minutes, then 45 cycles of 95°C for 20 seconds, 60°C for 30 seconds, and 72°C for 30seconds.

Detection of *PIK3CA* mutations by Sanger sequencing
----------------------------------------------------

For sequence analysis, PCR products were purified by PCR Product Purification Kit (Generalbiol, Anhui, China) and subjected to bidirectional dye-terminator sequencing using M13 forward primer 5′-TGTAAAACGACGGCCAGT-3′ for exon 9 amplicon and exon 20 reverse primer 5′-CCTATG-CAATCGGTCTTTGC-3′ for exon 20 amplicon. Sequencing fragments were detected by capillary electrophoresis using the ABI 3730xl DNA analyzer (Applied Biosystems, Carlsbad, CA, USA) and then analyzed by SnapGene Viewer 4.2.6. The mutations were identified by manual review.

Statistical analysis
--------------------

The relations between *PIK3CA* mutation statuses and clinicopathological characteristics were assessed by the Pearson chi-squared tests using SPSS software v19.0.0 (IBM, NY, USA). The HR of *PIK3CA* mutation as well as clinicopathological variables was calculated by the Cox proportional hazards regression model in univariate analysis. Based on the PFS in different mutation conditions, the Kaplan--Meier survival curves were drawn using GraphPad Prism software v5.01 (GraphPad, San Diego, CA, USA) and the significant differences were displayed by the log-rank test (SPSS v 19.0.0, IBM). Statistical significance was considered as *P*\<0.05.

Results
=======

Somatic mutations in breast cancer patients from Central China
--------------------------------------------------------------

To investigate the somatic mutations in breast cancer, 24 primary tumor samples were analyzed using targeted next generation sequencing (NGS). A mean coverage depth of 8,525× was achieved. 94.4% of amplicons were covered at \>500× depth. After SNV and indel calling, a total of 93 mutations were detected, including 27 synonymous SNVs, 48 nonsynonymous SNVs, 3 stopgains, 3 splicings, 10 frameshift deletions, 1 nonframeshift deletion, and 1 frameshift insertion. The overall mutation frequency was 2.75 nonsilent mutations (range of 0--12 mutations) per sample. As shown in [Figure 1](#f1-cmar-11-1473){ref-type="fig"}, the most frequently mutated gene was *TP53* (41.7%, 10 of the 24 patients) with various mutation types (missense mutation, nonsense mutation, frameshift insertion, and splicing). *PIK3CA* mutation was found in 33% of the samples, which ranked as the second highest mutated gene. All of the *PIK3CA* mutations were hotspot mutations including three E542K, three E545K, and two H1047R ([Table S2](#SD4-cmar-11-1473){ref-type="supplementary-material"}). This much higher mutation rate in *PIK3CA* exon 9 (75%) in breast cancer was quite different from previous reports[@b19-cmar-11-1473],[@b32-cmar-11-1473]--[@b34-cmar-11-1473] which attracted our attention. Besides, we examined the clinicopathological variables of these patients and found that the samples harbored exon 9 mutations were HER2-negative tumors and all belonged to luminal B molecular subtype ([Table S2](#SD4-cmar-11-1473){ref-type="supplementary-material"}). Furthermore, the only two tumor-relapsed cases were also from the group with exon 9 mutations, which demonstrated that exon 9 mutations might be related to poor prognosis ([Table S2](#SD4-cmar-11-1473){ref-type="supplementary-material"}). Therefore, we hypothesized that the proportion of *PIK3CA* exon 9 mutations was much higher in the female breast cancer patients from our area (Central China) than the other regions, and this preference was correlated with special clinicopathological characteristics and tumor prognosis.

*PIK3CA* mutations detection in archival FFPE tissues
-----------------------------------------------------

To verify our hypothesis, the mutations in exon 9 and exon 20 of *PIK3CA* gene were examined by direct sequencing in 537 primary breast tumor samples including the 24 specimens analyzed by NGS to validate the results of sequencing. Among the succeeded sequenced 494 (92%) samples, *PIK3CA* mutations were determined in 188 (38%) tumors, including 74 mutations in exon 9, 106 mutations in exon 20, and 8 in both exons 9 and 20 ([Table 1](#t1-cmar-11-1473){ref-type="table"}). The hotspot mutations accounted for 74.6% of total mutations (153/205) in which E542K (p.542), E545K (p.545), and H1047R/L (p.1047) were found in 28, 34, and 91 patients, respectively, with p.1047 ranking the highest ([Table 1](#t1-cmar-11-1473){ref-type="table"}). Seventeen patients carried two mutations and two of them had H1047R simultaneous with E542K or E545K, which had never been reported before ([Table 1](#t1-cmar-11-1473){ref-type="table"}). Meanwhile, we characterized 52 non-hotspot mutations in which 1 silent and 5 nonsense mutations were observed in 37 patients ([Table 1](#t1-cmar-11-1473){ref-type="table"}).

In addition, we found 14 new *PIK3CA* mutations in exon 9 and 20 in breast cancers, which have not been reported by COSMIC. Among the newly found mutations, 8 of them were located in exon 9, 4 in exon 20, and the other 2 in both exon 9 and 20 ([Table S3](#SD5-cmar-11-1473){ref-type="supplementary-material"}). Whether they have any clinical significance needs to be studied further. Thus, these new mutations were not taken for the following analyses in this study.

Association of *PIK3CA* gene mutations with clinicopathological data
--------------------------------------------------------------------

As shown in [Table 2](#t2-cmar-11-1473){ref-type="table"}, *PIK3CA* mutations were positively associated with ER-positive (*P*=0.016), PR-positive (*P*=0.007), and low Ki67 labeling index (*P*=0.001) tumors. Meanwhile, they were negatively correlated with triple-negative breast cancer subtype (*P*=0.003), but were not associated with age at diagnosis, tumor stage, lymph node status, tumor size, or HER2 status.

We further investigated the relationships between clinicopathological features and *PIK3CA* mutation distributions, including the exon 9/20 and hotspot mutations (p.542/545 and p.1047; [Table 2](#t2-cmar-11-1473){ref-type="table"}). ER and PR positive were also significantly correlated with mutations in exon 9 and at p.542/545. Besides, the low Ki67 index was found in patients with exon 20 and p.1047 mutations. Meanwhile, triple-negative breast cancer patients had much less p.1047 mutations (*P*=0.012). In addition, p.1047 mutations were significantly associated with old diagnosis age (≥40 years old; *P*=0.043).

Compared to breast cancers with *PIK3CA* hotspot mutations, cancers carrying non-hotspot mutations were more likely to belong to triple-negative subtype (*P*=0.006) and be larger in tumor size ([Table 2](#t2-cmar-11-1473){ref-type="table"}). When analyzed by mutation burden, cancers with two mutations were more likely to be larger in tumor size compared with cancers harbored only one mutation ([Table 2](#t2-cmar-11-1473){ref-type="table"}).

Associations of *PIK3CA* gene mutations with prognosis
------------------------------------------------------

As shown in [Table 2](#t2-cmar-11-1473){ref-type="table"}, when we predicted the prognosis of the patients using the NPI method, no significant association was observed between various *PIK3CA* mutation statuses and prognosis.

Furthermore, prognosis analysis was conducted among 303 breast cancer patients with a median follow-up of 35 months. The Cox proportional hazards model and the Kaplan--Meier survival curve were used to evaluate the correlation between PFS rate or OS rate of breast cancer patients and *PIK3CA* mutation statuses.

In the univariate analysis, patients with old prognostic age (*P*=0.034) and small tumor size (*P*=0.033) exhibited better PFS, while old prognostic age (*P*=0.025) also correlated with better OS ([Table 3](#t3-cmar-11-1473){ref-type="table"}). However, *PIK3CA* mutation frequency was not statistically significantly associated with PFS (HR\[95% CI\]=1.257\[0.732--2.160\], *P*=0.407), OS (HR\[95% CI\]=1.946\[0.987--3.837\], *P*=0.055), as well as their exon 9, exon 20, and hotspot mutations ([Table 3](#t3-cmar-11-1473){ref-type="table"}).

When examined by Kaplan--Meier estimate and log-rank test, the PFS of total patients with *PIK3CA* mutations was almost the same as wild-type patients, while the OS was significantly better in the total patients with *PIK3CA* mutations ([Figure 2](#f2-cmar-11-1473){ref-type="fig"}). However, there were no differences in PFS/OS between mutation and wild-type groups when examined by exon 9, exon 20, and hotspot mutations p.542/545 and p.1047 ([Figures S1](#SD1-cmar-11-1473){ref-type="supplementary-material"} and [S2](#SD2-cmar-11-1473){ref-type="supplementary-material"}). Besides, *PIK3CA* mutations significantly improved the OS of the patients with old diagnosis age, low Ki67 labeling index, or luminal/HER2-enriched subtypes ([Figure 3](#f3-cmar-11-1473){ref-type="fig"}). Also as better prognostic effectors, exon 20 mutations as well as the hotspot p.1047 mutations were significantly associated with the PFS of the patients in HER2-negative or low Ki67 labeling index subgroups ([Figure 4](#f4-cmar-11-1473){ref-type="fig"}) and the OS of the patients diagnosed as luminal/HER2-enriched subtypes ([Figure 3](#f3-cmar-11-1473){ref-type="fig"}). In contrast, exon 9 mutations and its hotspot p.542/545 mutations were found in the patients with worse PFS, who belonged to PR-positive or lymph node-negative subgroups ([Figure 4](#f4-cmar-11-1473){ref-type="fig"}).

When performing the univariate Cox analysis according to different clinicopathological parameters, a significant difference in PFS was observed between prognosis and exon 9 as well as p.542/545 hotspot mutations in PR-positive or lymph node-negative subgroups, exon 20 in HER2-negative or low Ki67 labeling index subgroups ([Table 4](#t4-cmar-11-1473){ref-type="table"}). In OS, a significantly better prognosis was found in total *PIK3CA* and exon 20 mutations patients with luminal/HER2-enriched subtypes, while total *PIK3CA* mutations patients with old diagnostic age had a better OS as well ([Table 4](#t4-cmar-11-1473){ref-type="table"}). These results were partially in accordance with the Kaplan--Meier analysis. Besides, no significance was detected between prognosis and *PIK3CA* mutation distribution/bias/burden under multiple other clinical, pathological, and molecular subtypes ([Table S4](#SD6-cmar-11-1473){ref-type="supplementary-material"}).

Discussion
==========

To study the clinicopathological and prognostic values of *PIK3CA* variants in the breast cancer patients from Central China, 494 patients were investigated, and new insight into the complexity of *PIK3CA* mutations was provided in this research. In general, the mutation frequency (38%) in this study is relatively high as most investigations reported \~30% mutation rate using the similar detection method ([Table 5](#t5-cmar-11-1473){ref-type="table"}).[@b21-cmar-11-1473],[@b24-cmar-11-1473],[@b26-cmar-11-1473],[@b35-cmar-11-1473]--[@b42-cmar-11-1473] Interestingly, the frequency rates of *PIK3CA* mutations fluctuated among the studies which had been done by different groups from distinct areas of China ([Table S5](#SD7-cmar-11-1473){ref-type="supplementary-material"}).[@b43-cmar-11-1473]--[@b54-cmar-11-1473] This might be partially due to the sensitivity of assay methods. However, considering the controversial results from the researches around the world as well as environmental factors and lifestyles playing roles in breast cancer, we hypothesized that *PIK3CA* mutations and its associated factors might show diversity roles among the populations from different regions.

Then, we identified a significant association of *PIK3CA* mutations with clinicopathological and molecular characteristics, such as luminal/HER2-enriched subtypes, ER-positive, PR-positive, and low Ki67 labeling index which were partly consistent with the literature.26,35,36,40,41,44,45,47 When we separately analyzed the mutations in exon 9 and exon 20, their differences on the relationships with the clinicopathological characteristics were identified and should be considered separately when used for disease monitoring, therapeutic effect evaluation, and prognosis prediction. Besides, the point mutation p.1047, non-hotspot mutations, and more mutation burdens related to specific clinical and biological features of breast cancer might play particular roles and need to be investigated in future.

Numerous investigators reported that *PIK3CA* mutations are associated with prognosis.[@b24-cmar-11-1473],[@b26-cmar-11-1473],[@b39-cmar-11-1473]--[@b41-cmar-11-1473],[@b43-cmar-11-1473],[@b44-cmar-11-1473] However, this association varies and even contradict among studies. Some of them showed better prognosis of the patients with *PIK3CA* mutations,[@b24-cmar-11-1473],[@b26-cmar-11-1473],[@b40-cmar-11-1473] and others believed worse outcome,[@b39-cmar-11-1473],[@b43-cmar-11-1473],[@b44-cmar-11-1473],[@b50-cmar-11-1473] while many researchers did not find any prognostic significance.[@b35-cmar-11-1473],[@b36-cmar-11-1473],[@b38-cmar-11-1473],[@b49-cmar-11-1473] In our study, interesting outcomes were explored when we tested the prognostic value of each *PIK3CA* mutation status in the subgroups separated according to different clinicopathological parameters. Firstly, total *PIK3CA* mutations exhibited disparate roles between FPS and OS in subgroups ([Figures 2](#f2-cmar-11-1473){ref-type="fig"} and [3](#f3-cmar-11-1473){ref-type="fig"}). Secondly, both exon 9 and exon 20 mutations correlated with FPS, but in diverse subgroups ([Figure 4](#f4-cmar-11-1473){ref-type="fig"}). Thirdly, only the effect of exon 20 mutations on the OS was identified ([Figure 3D](#f3-cmar-11-1473){ref-type="fig"}). Furthermore, exon 9 and exon 20 mutations revealed completely converse roles in the prognosis ([Figures 3D](#f3-cmar-11-1473){ref-type="fig"} and [4](#f4-cmar-11-1473){ref-type="fig"}). Moreover, the hotspot mutations were in perfect accord with their exons ([Figures 3D, E](#f3-cmar-11-1473){ref-type="fig"} and [4](#f4-cmar-11-1473){ref-type="fig"}). These results demonstrated that the variant status of *PIK3CA* mutations played different roles in the prognosis of breast cancer patients in our area.

In addition, when checking our samples, we realized that 60% of tumors in our study belonged to luminal B molecular subtype, which was extremely higher than the ratio in the other studies (\~30%). This phenomenon also demonstrated that breast cancer patients in our area might have some specific preferences in genetic and clinicopathological features. However, the reasons and mechanisms need to be elucidated in future.

Limitations
===========

This study still has some limitations. Firstly, all the samples were from a single center with a relatively small sample size. Although we identified some rules in the clinicopathological features, prognostic relevance, and *PIK3CA* mutation preferences, the sample size in the subgroups (stage I tumors, tumors with two mutations, and the relapsed patients) was quite small which made the results not that solid. Secondly, the followup times for most patients were too short. As \>80% of breast cancer patients survive for \>5 years after diagnosis, longer follow-up time is needed. Moreover, the effect and association of adjuvant systemic therapy with *PIK3CA* mutation status were not evaluated in this study, which might influence the progression-free/overall survival rate. Furthermore, the oncogenetic mutations in other exons were not examined, which might contribute to the prognosis of the patients.

Conclusion
==========

*PIK3CA* mutations were detected using Sanger sequencing combined with targeted NGS in 38% of breast cancer patients from a single hospital in Central China. Different from the other studies, 60% of breast cancer patients were diagnosed with luminal B tumors. *PIK3CA* mutations were associated with ER-positive, PR-positive, low Ki67 labeling index, and luminal/HER2-enriched subtypes, while exon 9, exon 20, hotspot mutations, and mutation burdens made distinct contributions. In addition, p.1047 mutations were significantly associated with older diagnosis age. Significant heterogeneity was identified in the univariable effect of *PIK3CA* mutation status on FPS and OS. *PIK3CA* mutations patients had a better OS, which was also showed in the older diagnostic age, PR-negative, low Ki67 labeling index, and luminal/HER2-enriched subgroups. As better prognostic markers, exon 20 and p.1047 hotspot mutations significantly persisted in the HER2-negative and low Ki67 labeling index subgroups (analyzed by FPS) as well as luminal/HER2-enriched subgroup (analyzed by OS). In contrast, exon 9 and p.542/545 hotspot mutations exhibited worse prognostic factors in PR-positive and lymph node-negative subgroups when assayed using FPS. Therefore, these results demonstrated that the mutation frequency, distribution, bias, and burden of *PIK3CA* were related to different clincopathological characteristics, prognosis, and might play different roles in breast cancer from Central China. These differences and relationships should be deeply studied and taken into consideration during disease management.

Supplementary materials
=======================

###### 

Progression-free Kaplan--Meier survival curves of the total patients.

**Note:** (**A**--**D**) PFS rate of total patients with exon 9 (**A**), p.542/545 (**B**), exon 20 (**C**), or p.1047 (**D**) mutations.

**Abbreviations:** Mut, mutation; PFS, progression-free survival; WT, wild-type.

###### 

Overall Kaplan--Meier survival curves of the total patients.

**Note:** (**A**--**D**) OS rate of total patients with exon 9 (**A**), p.542/545 (**B**), exon 20 (**C**), or p.1047 (**D**) mutations.

**Abbreviations:** Mut, mutation; OS, overall survival; WT, wild-type.

###### 

Clinical, pathological, and biological features of breast cancer patients

  Parameters                 Category    Number of patients                                  Percentage                 Note
  -------------------------- ----------- --------------------------------------------------- -------------------------- ----------------------------------------------
                                                                                                                        
  Total                                  494                                                 100.00                     Eligible samples for analysis in 537 samples
  Age (years)                \<40        91                                                  18.40                      Age range: 25--89 years old
  ≥40                        403         81.58                                               Median age: 48 years old   
  Tumor stage                I           12                                                  2.43                       
  II                         250         50.61                                                                          
  III                        205         41.50                                                                          
  Unknown                    27          5.47                                                                           
  Lymph node status          0           229                                                 46.36                      
  1--3                       108         21.86                                                                          
  \>3                        131         26.52                                                                          
  Unknown                    26          5.26                                                                           
  Tumor size (cm)            \<2         124                                                 25.10                      Tumor size range: 0.3--12 cm
  2--5                       315         63.77                                               Median size: 2.6 cm        
  ≥5                         54          10.93                                                                          
  Unknown                    1           0.20                                                                           
  Molecular subtypes         Luminal A   69                                                  13.97                      
  Luminal B                  300         60.73                                                                          
  HER2+                      66          13.36                                                                          
  Triple negative            57          11.54                                                                          
  Unknown                    2           0.40                                                                           
  ER                         Positive    357                                                 72.27                      
  Negative                   133         26.92                                                                          
  Unknown                    4           0.81                                                                           
  PR                         Positive    319                                                 64.57                      
  Negative                   172         34.82                                                                          
  Unknown                    3           0.61                                                                           
  HER2                       Positive    172                                                 34.82                      
  Negative                   315         63.77                                                                          
  Unknown                    7           1.42                                                                           
  Ki67 (%)                   ≤30         250                                                 50.61                      
  \>30                       230         46.56                                                                          
  Unknown                    14          2.83                                                                           
  Follow-up data collected   Total       303                                                 61.34                      Follow-up period: 5--97 months
  Relapsed or second tumor   28          9.24[a](#tfn8-cmar-11-1473){ref-type="table-fn"}    Median time: 35 months     
  Died                       46          15.18[a](#tfn8-cmar-11-1473){ref-type="table-fn"}                              

**Note:**

Percentage of the total follow-up data collected samples.

**Abbreviations:** ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor.

###### 

General clinical and pathological features of breast cancers used for targeted sequencing (n=24)

  Patient ID   *PIK3CA* mutation   Age (years)   Tumor stage   Lymph node status   Tumor size (cm)   Molecular subtype   ER         PR         HER2       Ki67      PFS (Month)   Note
  ------------ ------------------- ------------- ------------- ------------------- ----------------- ------------------- ---------- ---------- ---------- --------- ------------- ----------
                                                                                                                                                                                  
  R160066      WT                  39            III           8                   3                 Luminal B           90%        90%        2+         20%       24            
  R160069      WT                  30            III           12                  3                 HER2+               Negative   Negative   3+         60%       37            
  R160070      WT                  31            III           0                   6                 Luminal B           30%        10%        Negative   50%       Unknown       
  R160071      WT                  32            II--III       2                   2                 Luminal B           70%        40%        2+         30%       40            
  R160080      WT                  35            II            4                   3                 Luminal B           50%        50%        1+         20%       Unknown       
  R160082      WT                  35            Unknown       23                  4.5               Luminal B           90%        30%        1+         Unknown   43            
  R160088      WT                  37            II--III       4                   1.6               Luminal B           80%        15%        3+         20%       44            
  R160090      E542K               37            II--III       1                   2.2               Luminal B           95%        5%         Negative   60%       35            Relapsed
  R160093      WT                  39            II--III       0                   3.5               Luminal B           95%        95%        2+         15%       40            
  R160104      WT                  43            II            2                   2                 Luminal B           100%       100%       Negative   30%       22            
  R160107      E545K               43            Unknown       24                  3.5               Luminal B           90%        30%        1+         30%       27            
  R160110      WT                  43            II--III       0                   2.2               Luminal B           90%        90%        3+         40%       29            
  R160111      WT                  43            III           0                   1                 Luminal B           40%        90%        3+         70%       23            
  R160114      WT                  44            II            0                   1.5               Luminal B           90%        90%        1+         60%       23            
  R160123      E545K               45            II            2                   2.3               Luminal B           95%        95%        Negative   35%       28            
  R160127      WT                  45            II            0                   1                 Luminal B           80%        70%        Negative   25%       21            
  R160130      WT                  45            III           1                   2.5               Triple negative     Negative   Negative   1+         80%       23            
  R160133      E542K               46            II            0                   4.2               Luminal B           95%        95%        Negative   25%       Unknown       
  R160138      WT                  46            III           0                   4                 Triple negative     Negative   Negative   Negative   80%       22            
  R160145      E542K               47            II            0                   1.8               Luminal B           50%        20%        Negative   75%       26            
  R160158      WT                  48            III           6                   1.3               Luminal B           30%        Negative   Negative   60%       28            
  R160161      E545K               49            Unknown       10                  8                 Luminal B           50%        50%        Negative   20%       36            Relapsed
  R160164      H1047R              50            II--III       0                   2                 Luminal B           3%         Negative   Negative   60%       27            
  R160169      H1047R              51            II            12                  2                 Luminal A           90%        30%        1+         8%        30            

**Abbreviations:** ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PFS, progression-free survival; PR, progesterone receptor; WT, wild-type.

###### 

New *PIK3CA* mutations in exons 9 and 20 in breast cancers (n=494)

  Exon   Nucleotide change                      Codon change                                 New mutation effect   Number of mutations
  ------ -------------------------------------- -------------------------------------------- --------------------- ---------------------
                                                                                                                   
  9      c.1618C\>G                             p.Leu540Val                                  Missense              1
  9      c.1621T\>C                             p.Ser541Pro                                  Missense              1
  9      c.1628T\>C                             p.Ile543Thr                                  Missense              1
  9      c.1628T\>G                             p.Ile543Ser                                  Missense              1
  9      c.1629C\>G                             p.Ile543Met                                  Missense              2
  9      c.1655G\>A                             p.Trp552\*                                   Nonsense              1
  20     c.3139_3140CA\>TG                      p.His1047Cys                                 Missense              1
  20     c.3206G\>A                             p.\*1069\*                                   Silent                1
  9      c.\[1621T\>C(+)1644delA\]              p.\[Ser541Pro(+)Lys548fs\*10\]               Frameshift            1
  9+20   c.\[1651C\>T(+)3117C\>T\]              p.\[Leu551Leu(+)Phe1039Phe\]                 Silent                1
  20     c.\[3120G\>A(+)3201G\>A\]              p.\[Met1040Ile(+)Leu1067Leu\]                Silent                1
  9+20   c.\[1644A\>G(+)3140A\>G(+)3178C\>T\]   p.\[Lys548Lys(+)His1047Arg(+)His1060Tyr\]    Missense              1
  20     c.\[3117C\>T(+)3140A\>G(+)3145G\>A\]   p.\[Phe1039Phe(+)His1047Arg(+)Gly1049Ser\]   Silent                1

###### 

Univariate Cox analysis of the correlation between *PIK3CA* mutation status and progression-free/overall survival according to different clinicopathological parameters

  Variables                          PFS                     OS                                  
  ---------------------------------- ----------------------- ----------- ----------------------- -----------
                                                                                                 
  **\<40 years old**                                                                             
   *PIK3CA* mutation vs wild-type    0.746 (0.298--10.866)   0.531       1.365 (0.463--4.022)    0.572
   Exon 9 mutation vs wild-type      0.554 (0.173--1.780)    0.322       1.345 (0.298--6.077)    0.700
   Exon 20 mutation vs wild-type     1.050 (0.336--3.282)    0.934       1.238 (0.339--4.519)    0.747
   p.542/545 mutation vs wild-type   0.382 (0.117--1.247)    0.111       0.995 (0.221--4.470)    0.995
   p.1047 mutation vs wild-type      0.894 (0.256--3.117)    0.860       1.133 (0.252--5.092)    0.871
  **≥40 years old**                                                                              
   *PIK3CA* mutation vs wild-type    1.632 (0.821--3.247)    0.163       2.545 (1.042--6.215)    **0.040**
   Exon 9 mutation vs wild-type      1.029 (0.403--2.628)    0.953       1.858 (0.440--7.837)    0.399
   Exon 20 mutation vs wild-type     1.977 (0.879--4.446)    0.099       2.283 (0.874--5.962)    0.092
   p.542/545 mutation vs wild-type   1.068 (0.380--3.003)    0.901       3.175 (0.431--23.373)   0.257
   p.1047 mutation vs wild-type      1.942 (0.819--4.607)    0.132       2.412 (0.840--6.928)    0.102
  **ER negative**                                                                                
   *PIK3CA* mutation vs wild-type    1.747 (0.589--5.181)    0.314       5.336 (0.699--40.709)   0.106
   Exon 9 mutation vs wild-type      1.507 (0.202--11.232)   0.689       --                      --
   Exon 20 mutation vs wild-type     1.711 (0.504--5.810)    0.389       3.824 (0.500--29.247)   0.196
   p.542/545 mutation vs wild-type   1.507 (0.202--11.232)   0.689       --                      --
   p.1047 mutation vs wild-type      1.497 (0.440--5.092)    0.518       3.312 (0.433--25.325)   0.248
  **ER positive**                                                                                
   *PIK3CA* mutation vs wild-type    1.060 (0.555--2.025)    0.860       1.583 (0.736--3.403)    0.240
   Exon 9 mutation vs wild-type      0.665 (0.303--1.459)    0.309       1.185 (0.410--3.425)    0.754
   Exon 20 mutation vs wild-type     1.707 (0.779--3.741)    0.182       1.714 (0.727--4.041)    0.219
   p.542/545 mutation vs wild-type   0.579 (0.253--1.324)    0.195       1.295 (0.390--4.295)    0.673
   p.1047 mutation vs wild-type      1.785 (0.744--4.279)    0.194       1.801 (0.684--4.738)    0.233
  **PR negative**                                                                                
   *PIK3CA* mutation vs wild-type    1.522 (0.657--3.526)    0.327       3.198 (0.953--10.729)   0.060
   Exon 9 mutation vs wild-type      1.888 (0.451--7.908)    0.384       --                      --
   Exon 20 mutation vs wild-type     1.347 (0.517--3.510)    0.542       2.099 (0.623--7.070)    0.231
   p.542/545 mutation vs wild-type   1.665 (0.397--6.975)    0.486       --                      --
   p.1047 mutation vs wild-type      1.159 (0.444--3.023)    0.763       1.860 (0.552--6.271)    0.317
  **PR positive**                                                                                
   *PIK3CA* mutation vs wild-type    0.983 (0.468--2.066)    0.964       1.396 (0.582--3.353)    0.455
   Exon 9 mutation vs wild-type      0.406 (0.170--0.973)    **0.043**   0.733 (0.246--2.187)    0.578
   Exon 20 mutation vs wild-type     2.014 (0.811--4.999)    0.131       1.880 (0.686--5.1479)   0.220
   p.542/545 mutation vs wild-type   0.340 (0.134--0.863)    **0.023**   0.786 (0.231--2.674)    0.700
   p.1047 mutation vs wild-type      2.317 (0.801--6.704)    0.121       2.258 (0.664--7.677)    0.192
  **HER2 negative**                                                                              
   *PIK3CA* mutation vs wild-type    1.496 (0.727--3.076)    0.274       2.168 (0.885--5.314)    0.091
   Exon 9 mutation vs wild-type      0.507 (0.221--1.166)    0.110       1.238 (0.373--4.112)    0.728
   Exon 20 mutation vs wild-type     3.039 (1.078--8.573)    **0.036**   2.156 (0.750--6.198)    0.154
   p.542/545 mutation vs wild-type   0.452 (0.187--1.096)    0.079       1.546 (0.366--6.526)    0.553
   p.1047 mutation vs wild-type      3.225 (0.991--10.488)   0.052       2.262 (0.685--7.472)    0.180
  **HER2 positive**                                                                              
   *PIK3CA* mutation vs wild-type    0.948 (0.410--2.193)    0.900       1.983 (0.630--6.239)    0.242
   Exon 9 mutation vs wild-type      1.709 (0.400--7.306)    0.470       1.964 (0.257--15.004)   0.515
   Exon 20 mutation vs wild-type     0.903 (0.370--2.205)    0.823       2.248 (0.627--8.065)    0.214
   p.542/545 mutation vs wild-type   1.483 (0.347--6.342)    0.595       1.683 (0.220--12.867)   0.616
   p.1047 mutation vs wild-type      0.873 (0.343--2.219)    0.776       2.502 (0.563--11.118)   0.228
  **Ki67 labeling index £30%**                                                                   
   *PIK3CA* mutation vs wild-type    1.672 (0.764--3.663)    0.199       2.977 (0.955--9.281)    0.600
   Exon 9 mutation vs wild-type      0.556 (0.221--1.399)    0.213       1.040 (0.233--4.637)    0.959
   Exon 20 mutation vs wild-type     2.838 (1.065--7.565)    **0.037**   3.099 (0.869--11.047)   0.081
   p.542/545 mutation vs wild-type   0.464 (0.171--1.262)    0.133       1.480 (0.192--11.378)   0.706
   p.1047 mutation vs wild-type      2.773 (0.958--8.027)    0.060       3.548 (0.805--15.642)   0.094
  **Ki67 labeling index \>30%**                                                                  
   *PIK3CA* mutation vs wild-type    1.270 (0.546--2.951)    0.579       1.716 (0.689--4.274)    0.246
   Exon 9 mutation vs wild-type      1.315 (0.398--4.343)    0.653       1.941 (0.458--8.234)    0.368
   Exon 20 mutation vs wild-type     1.409 (0.492--4.039)    0.523       1.611 (0.552--4.705)    0.383
   p.542/545 mutation vs wild-type   1.267 (0.384--4.186)    0.697       1.881 (0.443--7.977)    0.391
   p.1047 mutation vs wild-type      1.478 (0.448--4.875)    0.521       1.661 (0.493--5.597)    0.413
  **Tumor stage I and II**                                                                       
   *PIK3CA* mutation vs wild-type    1.070 (0.557--2.059)    0.838       1.817 (0.808--4.086)    0.148
   Exon 9 mutation vs wild-type      0.578 (0.247--1.349)    0.205       0.790 (0.270--2.314)    0.667
   Exon 20 mutation vs wild-type     1.584 (0.744--3.370)    0.233       2.301 (0.904--5.853)    0.080
   p.542/545 mutation vs wild-type   0.490 (0.194--1.237)    0.131       0.837 (0.248--2.825)    0.837
   p.1047 mutation vs wild-type      1.572 (0.691--3.577)    0.281       2.510 (0.859--7.333)    0.092
  **Tumor stage III**                                                                            
   *PIK3CA* mutation vs wild-type    1.519 (0.498--4.635)    0.463       2.331 (0.514--10.581)   0.273
   Exon 9 mutation vs wild-type      1.359 (0.309--5.979)    0.685       --                      --
   Exon 20 mutation vs wild-type     1.867 (0.428--8.137)    0.406       1.201 (0.265--5.442)    0.812
   p.542/545 mutation vs wild-type   1.225 (0.277--5.414)    0.789       --                      --
   p.1047 mutation vs wild-type      1.498 (0.342--6.550)    0.592       0.911 (0.200--4.149)    0.904
  **Lymph node negative**                                                                        
   *PIK3CA* mutation vs wild-type    1.002 (0.423--2.372)    0.997       1.626 (0.606--4.360)    0.334
   Exon 9 mutation vs wild-type      0.236 (0.085--0.655)    **0.006**   0.444 (0.127--1.545)    0.202
   Exon 20 mutation vs wild-type     2.214 (0.742--6.612)    0.154       2.399 (0.766--7.513)    0.133
   p.542/545 mutation vs wild-type   0.107 (0.029--0.403)    **0.001**   0.401 (0.090--1.790)    0.231
   p.1047 mutation vs wild-type      3.065 (0.717--13.102)   0.131       3.120 (0.712--13.673)   0.131
  **Lymph node positive**                                                                        
   *PIK3CA* mutation vs wild-type    1.428 (0.681--2.996)    0.346       2.279 (0.848--6.124)    0.102
   Exon 9 mutation vs wild-type      1.926 (0.586--6.328)    0.280       4.403 (0.593--32.711)   0.147
   Exon 20 mutation vs wild-type     1.283 (0.558--2.951)    0.557       1.669 (0.570--4.892)    0.350
   p.542/545 mutation vs wild-type   1.687 (0.514--5.540)    0.389       4.059 (0.546--30.159)   0.171
   p.1047 mutation vs wild-type      1.132 (0.492--2.600)    0.771       1.471 (0.502--4.309)    0.482
  **Tumor size \<5 cm**                                                                          
   *PIK3CA* mutation vs wild-type    1.074 (0.606--1.905)    0.806       1.584 (0.784--3.200)    0.200
   Exon 9 mutation vs wild-type      0.619 (0.298--1.283)    0.197       1.101 (0.387--3.129)    0.857
   Exon 20 mutation vs wild-type     1.530 (0.766--3.058)    0.228       1.602 (0.730--3.516)    0.240
   p.542/545 mutation vs wild-type   0.553 (0.257--1.191)    0.130       1.216 (0.372--3.983)    0.746
   p.1047 mutation vs wild-type      1.704 (0.801--3.623)    0.166       1.839 (0.767--4.410)    0.172
  **Tumor size ≥5 cm**                                                                           
   *PIK3CA* mutation vs wild-type    3.231 (0.407--25.614)   0.267       --                      --
   Exon 9 mutation vs wild-type      --                      --          --                      --
   Exon 20 mutation vs wild-type     3.231 (0.407--25.614)   0.267       --                      --
   p.542/545 mutation vs wild-type   --                      --          --                      --
   p.1047 mutation vs wild-type      0.286 (0.026--3.161)    0.307       --                      --
  **Luminal and HER2 subtypes**                                                                  
   *PIK3CA* mutation vs wild-type    1.323 (0.752--2.327)    0.332       2.125 (1.032--4.375)    **0.041**
   Exon 9 mutation vs wild-type      0.723 (0.351--1.488)    0.378       1.254 (0.443--3.550)    0.670
   Exon 20 mutation vs wild-type     1.969 (0.988--3.923)    0.054       2.337 (1.024--5.331)    **0.044**
   p.542/545 mutation vs wild-type   0.637 (0.298--1.361)    0.244       1.373 (0.421--4.478)    0.600
   p.1047 mutation vs wild-type      1.945 (0.917--4.125)    0.083       2.493 (0.971--6.399)    0.058
  **Triple negative subtype**                                                                    
   *PIK3CA* mutation vs wild-type    0.720 (0.083--6.247)    0.766       0.720 (0.083--6.247)    0.766
   Exon 9 mutation vs wild-type      --                      --          --                      --
   Exon 20 mutation vs wild-type     0.255 (0.026--2.463)    0.237       0.255 (0.026--2.463)    0.237
   p.542/545 mutation vs wild-type   --                      --          --                      --
   p.1047 mutation vs wild-type      0.255 (0.026--2.463)    0.237       0.255(0.026--2.463)     0.237

**Note:** *P*\<0.05 was considered statistically significant and those values are shown in bold.

**Abbreviations:** ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; OS, overall survival; PFS, progression-free survival; PR, progesterone receptor.

###### 

Comparison of association between *PIK3CA* mutations and various clinicopathological features in different areas in China

  Authors                          Year of publication   Area                   No. of patients   *PIK3CA* mutation   Sample type        Methods            Association between PIK3CA mutations and clinicopathological characteristics
  -------------------------------- --------------------- ---------------------- ----------------- ------------------- ------------------ ------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                                                            
  Hu et al[@b55-cmar-11-1473]      2018                  Changsha, Hunan        68                33.82%              Peripheral blood   Targeted NGS       *PIK3CA* mutations: worse progression-free survival
  Deng et al[@b56-cmar-11-1473]    2019                  Chengdu, Sichun        507               46.5%               FTS                Targeted NGS       *PIK3CA* mutations: ER positive, PR positive, HER3 negative; two or three mutations in PIK3CA: poor prognosis for overall survival
  Chen et al[@b57-cmar-11-1473]    2018                  Shanghai               149               43.6%               FTS                Targeted NGS       *PIK3CA* mutations: older age, ER positive, PR positive
  Cheng et al[@b58-cmar-11-1473]   2017                  Luzhou, Sichun         32                28.12%              FFPE               DS                 *PIK3CA* mutations: more invasiveness lymph node, bigger tumor size
  Yuan et al[@b59-cmar-11-1473]    2015                  Beijing                729               28.3%               FTS                DS                 *PIK3CA* mutations: ER positive, PR positive, less response to neoadjuvant chemotherapy
  Wang et al[@b60-cmar-11-1473]    2015                  Xining, Qinghai        25                32%                 FTS                DS                 Not detected
  Liu et al[@b61-cmar-11-1473]     2015                  Dalian, Liaoning       80                32.5%               FFPE               Targeted NGS       No significance
  Deng et al[@b62-cmar-11-1473]    2015                  Chengdu, Sichun        288               15.6%               FFPE               DS                 *PIK3CA* mutations: poor outcome of ER-positive breast cancer
  Zhang et al[@b63-cmar-11-1473]   2014                  Beijing                93                32.3%               FTS                xTAG liquid chip   *PIK3CA* mutations: patients' clinical response to neoadjuvant chemotherapy
  Bai et al[@b64-cmar-11-1473]     2014                  Xi'an Shaanxi          105               35.2%               FFPE               Targeted NGS       *PIK3CA* mutations: older age
  Tong et al[@b65-cmar-11-1473]    2012                  Guangzhou, Guangdong   120               7.5%                FTS                MA                 *PIK3CA* mutations: older age
  Li et al[@b66-cmar-11-1473]      2010                  Shanghai               233               19.7%               FFPE               DS                 *PIK3CA* mutations: high grade, ER positive, PR positive, PTEN positive
  Current study                    2018                  Hefei, Anhui           494               38.06%              FFPE               DS                 *PIK3CA* mutations: luminal and HER2 positive, ER positive, PR positive, low Ki67 index, better overall survival; exon 9 mutations: worse progression-free survival; exon 20 mutations: better progression- free survival and overall survival; H1047 mutations: older age, better progression-free survival and overall survival; non-hotspot mutations: larger tumor size

**Abbreviations:** DS, direct sequencing; ER, estrogen receptor; FFPE, formalin-fixed, paraffin-embedded tissue samples; FTS, frozen tissue samples; HER3, human epidermal growth factor receptor 3; MA, MassARRAY; NGS, next generation sequencing; PR, progesterone receptor.
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![Somatic mutations of 24 significant mutated genes in 24 breast cancer patients.\
**Notes:** The figure shows an overview of genomic alterations (right legend) in particular genes (rows) affecting individual samples (columns). The missense mutation, nonsense mutation, frame shift insertion, frame shift deletion, in frame deletion, splice site mutation, and multiple mutation are shown as green, red, purple, blue, brown, yellow, and black, respectively. Left legend denotes the percentage of mutations in 24 breast cancer samples and right plot represents the total number of mutations for each gene.](cmar-11-1473Fig1){#f1-cmar-11-1473}

![Kaplan--Meier survival curves according to *PIK3CA* genotype for (**A**) progression-free survival and (**B**) overall survival of the total patients.\
**Abbreviations:** Mut, mutation; WT, wild-type.](cmar-11-1473Fig2){#f2-cmar-11-1473}

![Overall Kaplan--Meier survival curves.\
**Note: (A,B**) OS rates of the *PIK3CA* mutations in ≥40 years old (**A**) and Ki67 labeling index ≤30% (**B**) subgroups; (**C**--**E**) OS rates of the luminal and HER2-enriched subtypes patients with *PIK3CA* (**C**), exon 20 (**D**), or p.1047 (**E**) mutations.\
**Abbreviations:** HER2, human epidermal growth factor receptor 2; Mut, mutation; OS, overall survival; WT, wild-type.](cmar-11-1473Fig3){#f3-cmar-11-1473}

![Progression-free Kaplan--Meier survival curves.\
**Note:** (**A**) PFS rates of the PR-positive patients with p.542/545 mutations; (**B,C**) PFS rates of the lymph node-negative patients with exon 9 (**B**) or p.542/545 (**C**) mutations; (**D,E**) PFS rates of the HER2-negative patients with exon 20 (**D**) or p.1047 (**E**) mutations; (**F,G**) PFS rates of the Ki67 labeling index ≤30% patients with exon 20 (**F**) or p.1047 (**G**) mutations.\
**Abbreviations:** HER2, human epidermal growth factor receptor 2; Mut, mutation; PFS, progression-free survival; PR, progesterone receptor; WT, wild-type.](cmar-11-1473Fig4){#f4-cmar-11-1473}

###### 

*PIK3CA* mutation profiles in exons 9 and 20 in breast cancers (n=494)

  Exon   Nucleotide change           Codon change                    Effect     Hotspot mutation   Frequency (%)   Number of mutations
  ------ --------------------------- ------------------------------- ---------- ------------------ --------------- ---------------------
                                                                                                                   
  9      c.1613A\>G                  p.Asp538Gly                     Missense   No                 \<1             1
  9      c.1615C\>T                  p.Pro539Ser                     Missense   No                 \<1             1
  9      c.1624G\>A                  p.Glu542Lys                     Missense   Yes                13.8            26
  9      c.1627A\>G                  p.Ile543Val                     Missense   No                 \<1             1
  9      c.1633G\>A                  p.Glu545Lys                     Missense   Yes                16.5            31
  9      c.1633G\>C                  p.Glu545Gln                     Missense   No                 \<1             1
  9      c.1634A\>C                  p.Glu545Ala                     Missense   No                 1.6             3
  9      c.1634A\>G                  p.Glu545Gly                     Missense   No                 \<1             2
  9      c.1636C\>A                  p.Gln546Lys                     Missense   No                 \<1             1
  9      c.1637A\>C                  p.Gln546Pro                     Missense   No                 \<1             1
  9      c.1637A\>G                  p.Gln546Arg                     Missense   No                 1.6             3
  9      c.1651C\>T                  p.Leu551Leu                     Silent     No                 \<1             1
  20     c.3120G\>A                  p.Met1040Ile                    Missense   No                 \<1             2
  20     c.3127A\>G                  p.Met1043Val                    Missense   No                 \<1             2
  20     c.3129G\>A                  p.Met1043Ile                    Missense   No                 \<1             1
  20     c.3139C\>T                  p.His1047Tyr                    Missense   No                 \<1             1
  20     c.3140A\>G                  p.His1047Arg                    Missense   Yes                38.3            72
  20     c.3140A\>T                  p.His1047Leu                    Missense   Yes                5.3             10
  20     c.3145G\>C                  p.Gly1049Arg                    Missense   No                 \<1             1
  20     c.3146G\>A                  p.Gly1049Asp                    Missense   No                 \<1             1
  20     c.3148G\>A                  p.Gly1050Ser                    Missense   No                 \<1             1
  20     c.3152G\>A                  p.Trp1051\*                     Nonsense   No                 \<1             1
  20     c.3153G\>A                  p.Trp1051\*                     Nonsense   No                 \<1             1
  20     c.3154A\>G                  p.Thr1052Ala                    Missense   No                 \<1             1
  20     c.3155C\>T                  p.Thr1052Ile                    Missense   No                 \<1             1
  20     c.3166G\>A                  p.Asp1056Asn                    Missense   No                 \<1             1
  20     c.3191A\>G                  p.Gln1064Arg                    Missense   No                 \<1             2
  20     c.3194A\>T                  p.His1065Leu                    Missense   No                 \<1             1
  9      c.\[1613A\>G(+)1633G\>A\]   p.\[Asp538Gly(+)Glu545Lys\]     Missense   Yes/No             \<1             1
  9      c.\[1613A\>G(+)1633G\>C\]   p.\[Asp538Gly(+)Glu545Gln\]     Missense   No                 \<1             1
  9+20   c.\[1624G\>A(+)3140A\>G\]   p.\[Glu542Lys(+)His1047Arg\]    Missense   Yes                \<1             1
  9+20   c.\[1624G\>A(+)3146G\>A\]   p.\[Glu542Lys(+)Gly1049Asp\]    Missense   Yes/No             \<1             1
  9+20   c.\[1633G\>A(+)3140A\>G\]   p.\[Glu545Lys(+)His1047Arg\]    Missense   Yes                \<1             1
  9+20   c.\[1633G\>A(+)3170G\>A\]   p.\[Glu545Lys(+)Trp1057\*\]     Nonsense   Yes/No             \<1             1
  9+20   c.\[1636C\>A(+)3166A\>G\]   p.\[Gln546Lys(+)Glu1056Asn\]    Missense   No                 \<1             1
  9+20   c.\[1637A\>G(+)3140A\>G\]   p.\[Gln546Arg(+)His1047Arg\]    Missense   Yes/No             \<1             1
  9+20   c.\[1637A\>G(+)3155C\>T\]   p.\[Gln546Arg(+)Thr1052Ile\]    Missense   No                 \<1             1
  9+20   c.\[1638G\>A(+)3140A\>G\]   p.\[Gln546Gln(+)His1047Arg\]    Missense   Yes/No             \<1             1
  20     c.\[3133G\>A(+)3152G\>A\]   p.\[Asp1045Asn(+)Trp1051\*\]    Nonsense   No                 \<1             1
  20     c.\[3137C\>T(+)3140A\>G\]   p.\[Ala1046Val(+)His1047Arg\]   Missense   Yes/No             \<1             1
  20     c.\[3140A\>G(+)3145G\>A\]   p.\[His1047Arg(+)Gly1049Ser\]   Missense   Yes/No             \<1             1
  20     c.\[3140A\>G(+)3146G\>A\]   p.\[His1047Arg(+)Gly1049Asp\]   Missense   Yes/No             \<1             1
  20     c.\[3140A\>G(+)3156A\>T\]   p.\[His1047Arg(+)Thr1052Thr\]   Missense   Yes/No             \<1             1
  20     c.\[3140A\>G(+)3166G\>A\]   p.\[His1047Arg(+)Asp1056Asn\]   Missense   Yes/No             \<1             1
  20     c.\[3148G\>A(+)3153G\>A\]   p.\[Gly1050Ser(+)Trp1051\*\]    Nonsense   No                 \<1             1
                                                                                                                   **Total =**188

###### 

Association between *PIK3CA* mutations and standard clinical, pathological, and biological features of breast cancer

  Parameters           Category        n           *PIK3CA*    Exon 9      Exon 20    p.542/545   p.1047      *PIK3CA* mutation   *PIK3CA* mutation burdens                                                                                               
  -------------------- --------------- ----------- ----------- ----------- ---------- ----------- ----------- ------------------- --------------------------- ----------- ---------- ----------- ----------- ---------- ----------- ----------- --------- -------
                                                                                                                                                                                                                                                          
  Total                                494         188 (38%)               82 (17%)               114 (23%)                       62 (13%)                                91 (18%)               153 (75%)   52 (25%)               171 (91%)   17 (9%)   
  Age (years)          \<40            91          28 (31%)    0.106       15 (16%)   0.974       15 (16%)    0.098               11 (12%)                    0.883       10 (11%)   **0.043**   21 (66%)    11 (34%)   0.202       24 (86%)    4 (14%)   0.294
  ≥ 40                 403             160 (40%)               67 (17%)               99 (25%)                51 (13%)                                        81 (20%)               132 (76%)   41 (24%)               147 (92%)   13 (8%)               
  Tumor stage          I               12          4 (33%)     0.216       0 (0%)     0.191       4 (33%)     0.413               0 (0%)                      0.280       3 (25%)    0.580       3 (75%)     1 (25%)    1.000       4 (100%)    0 (0%)    0.776
  II                   250             105 (42%)               46 (18%)               63 (25%)                35 (14%)                                        51 (20%)               86 (75%)    28 (25%)               96 (91%)    9 (9%)                
  III                  205             70 (34%)                31 (15%)               43 (21%)                23 (11%)                                        35 (17%)               58 (75%)    19 (25%)               63 (90%)    7 (10%)               
  Unknown              27              9                       5                      4                       4                                               2                      6           4                      8           1                     
  Lymph node status    0               229         86 (38%)    0.696       34 (15%)   0.543       54 (24%)    0.930               25 (11%)                    0.637       41 (18%)   0.780       66 (70%)    28 (30%)   0.199       78 (91%)    8 (9%)    0.391
  1--3                 108             45 (42%)                21 (19%)               26 (24%)                15 (14%)                                        19 (18%)               34 (72%)    13 (28%)               43 (96%)    2 (4%)                
  \>3                  131             48 (37%)                23 (18%)               29 (22%)                18 (14%)                                        27 (21%)               45 (83%)    9 (17%)                42 (88%)    6 (12%)               
  Unknown              26              9                       4                      5                       4                                               4                      8           2                      8           1                     
  Tumor size (cm)      \<2             124         42 (34%)    0.523       19 (15%)   0.401       24 (19%)    0.209               14 (11%)                    0.179       22 (18%)   0.917       36 (84%)    7 (16%)    0.071       41 (98%)    1 (2%)    0.074
  2--5                 315             125 (40%)               57 (18%)               72 (23%)                45 (14%)                                        58 (18%)               103 (75%)   34 (25%)               113 (90%)   12 (10%)              
  ≥5                   54              20 (37%)                6 (11%)                17 (31%)                3 (6%)                                          11 (20%)               14 (58%)    10 (42%)               16 (80%)    4 (20%)               
  Unknown              1               1                       0                      1                       0                                               0                      0           1                      1           0                     
  Molecular subtypes   Luminal A       69          31 (45%)    **0.003**   15 (21%)   0.069       17 (25%)    0.114               9 (13%)                     0.163       13 (19%)   **0.012**   22 (67%)    11 (33%)   **0.006**   29 (94%)    2 (6%)    0.498
  Luminal B            300             120 (40%)               54 (18%)               72 (24%)                43 (14%)                                        58 (19%)               101 (78%)   29 (22%)               110 (92%)   10 (8%)               
  HER2+                66              27 (41%)                10 (15%)               18 (27%)                8 (12%)                                         17 (26%)               25 (86%)    4 (14%)                25 (93%)    2 (7%)                
  Triple               57              9 (16%)                 3 (5%)                 6 (11%)                 2 (4%)                                          2 (4%)                 4 (36%)     7 (64%)                7 (78%)     2 (22%)               
  Negative                                                                                                                                                                                                                                                
  Unknown              2               1                       0                      1                       0                                               1                      1           1                      0           1                     
  ER                   Positive        357         148 (41%)   **0.014**   68 (19%)   **0.025**   87 (24%)    0.260               57 (16%)                    **0.049**   70 (20%)   0.334       127 (79%)   33 (21%)   0.708       136 (92%)   12 (8%)   0.670
  Negative             133             39 (29%)                14 (11%)               26 (20%)                12 (9%)                                         21 (16%)               33 (77%)    10 (23%)               35 (90%)    4 (10%)               
  Unknown              4               1                       0                      1                       0                                               1                      1           1                      0           1                     
  PR                   Positive        319         134 (42%)   **0.015**   61 (19%)   **0.050**   80 (25%)    0.139               53 (17%)                    0.026       64 (20%)   0.235       117 (81%)   28 (19%)   0.302       123 (92%)   11 (8%)   0.787
  Negative             172             53 (31%)                21 (12%)               33 (19%)                16 (9%)                                         27 (16%)               43 (74%)    15 (26%)               48 (91%)    5 (9%)                
  Unknown              3               1                       0                      1                       0                                               1                      1           1                      0           1                     
  HER2                 Positive        172         69 (40%)    0.519       26 (15%)   0.507       47 (27%)    0.111               22 (13%)                    0.896       36 (21%)   0.303       58 (76%)    18 (24%)   0.691       62 (90%)    7 (10%)   0.564
  Negative             315             117 (37%)               55 (18%)               66 (21%)                39 (12%)                                        54 (17%)               93 (74%)    33 (26%)               108 (92%)   9 (8%)                
  Unknown              7               2                       1                      1                       1                                               1                      2           1                      1           1                     
  Ki67 (%)             ≤30             250         114 (46%)   **0.001**   46 (18%)   0.424       72 (29%)    **0.002**           33 (13%)                    0.847       62 (25%)   **0.000**   95 (80%)    27 (22%)   0.189       106 (93%)   8 (7%)    0.317
  \>30                 230             71 (31%)                36 (16%)               39 (17%)                29 (13%)                                        26 (11%)               55 (70%)    24 (30%)               63 (89%)    8 (11%)               
  Unknown              14              3                       0                      3                       0                                               3                      3           1                      2           1                     
  NPI                  Good (2--3.4)   82          35 (43%)    0.671       15 (18%)   0.301       21 (26%)    0.662               11 (13%)                    0.501       17 (21%)   0.788       28 (78%)    8 (22%)    0.883       34 (97%)    1 (3%)    0.392
  Moderate             213             79 (37%)                29 (14%)               53 (25%)                22 (10%)                                        42 (20%)               64 (74%)    23 (26%)               71 (90%)    8 (10%)               
  (3.4--5.4)                                                                                                                                                                                                                                              
  Poor (\>5.4)         155             59 (38%)                30 (19%)               33 (21%)                22 (14%)                                        27 (17%)               49 (75%)    16 (25%)               53 (90%)    6 (10%)               
  Unknown              44              15                      8                      7                       7                                               5                      12          5                      13          2                     

**Note:** *P*\<0.05 was considered statistically significant and those values are shown in bold.

**Abbreviations:** ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; Mut, mutant; NPI, Nottingham Prognostic Index; PR, progesterone receptor.

###### 

Univariate Cox analysis of the correlation between clinicopathological parameters and progression-free/overall survival of breast cancer patients

  Variables                              PFS                    OS                                  
  -------------------------------------- ---------------------- ----------- ----------------------- -----------
                                                                                                    
  **Age (years**)                                                                                   
  \<40 vs ≥40                            1.805 (1.044--3.121)   **0.034**   2.050 (1.092--3.848)    **0.025**
  **Tumor stage**                                                                                   
  I and II vs III                        1.692 (0.976--2.935)   0.061       1.465 (0.769--2.792)    0.245
  **Lymph node status**                                                                             
  Positive vs negative                   0.764 (0.452--1.290)   0.313       0.944 (0.521--1.711)    0.850
  **Tumor size**                                                                                    
  \<5 cm vs ≥5 cm                        0.476 (0.240--0.943)   **0.033**   0.493 (0.229--1.062)    0.071
  **Molecular subtypes**                                                                            
  Luminal and HER2+ vs triple negative   1.264 (0.572--2.791)   0.563       0.939 (0.417--2.110)    0.878
  **ER**                                                                                            
  Positive vs negative                   1.162 (0.685--1.971)   0.579       1.114 (0.600--2.068)    0.732
  **PR**                                                                                            
  Positive vs negative                   1.469 (0.887--2.431)   0.135       1.403 (0.782--2.518)    0.257
  **HER2**                                                                                          
  Positive vs negative                   0.735 (0.433--1.246)   0.253       0.737 (0.396--1.371)    0.335
  **Ki67**                                                                                          
  ≤30% vs \>30%                          0.980 (0.583--1.646)   0.939       0.725 (0.389--1.349)    0.309
  ***PIK3CA* mutational status**                                                                    
  *PIK3CA* mutation vs wild-type         1.257 (0.732--2.160)   0.407       1.946 (0.987--3.837)    0.055
  Exon 9 mutation vs wild-type           0.794 (0.389--1.621)   0.527       1.444 (0.515--4.050)    0.485
  Exon 20 mutation vs wild-type          1.696 (0.883--3.259)   0.113       1.950 (0.907--4.194)    0.087
  p.542/545 mutation vs wild-type        0.731 (0.346--1.547)   0.413       1.646 (0.508--5.329)    0.406
  p.1047 mutation vs wild-type           1.662 (0.819--3.371)   0.159       2.2025 (0.857--4.783)   0.108

**Note:** *P*\<0.05 was considered statistically significant and those values are shown in bold.

**Abbreviations:** ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; OS, overall survival; PFS, progression-free survival; PR, progesterone receptor.

###### 

Univariate Cox analysis of the correlation between *PIK3CA* mutation status and progression-free/overall survival according to different clinicopathological parameters

  Variables                         PFS                    OS                                  
  --------------------------------- ---------------------- ----------- ----------------------- -----------
                                                                                               
  **≥40 years old**                                                                            
  *PIK3CA* mutation vs wild-type    1.632 (0.821--3.247)   0.163       2.545 (1.042--6.215)    **0.040**
  **PR positive**                                                                              
  p.542/545 mutation vs wild-type   0.397 (0.169--0.932)   **0.034**   0.980 (0.293--3.282)    0.974
  **HER2 negative**                                                                            
  Exon 20 mutation vs wild-type     3.039 (1.078--8.573)   **0.036**   2.156 (0.750--6.198)    0.154
  **Ki67 labeling index £30%**                                                                 
  Exon 20 mutation vs wild-type     2.838 (1.065--7.565)   **0.037**   3.099 (0.869--11.047)   0.081
  **Lymph node negative**                                                                      
  Exon 9 mutation vs wild-type      0.236 (0.085--0.655)   **0.006**   0.444 (0.127--1.545)    0.202
  p.542/545 mutation vs wild-type   0.107 (0.029--0.403)   **0.001**   0.401 (0.090--1.790)    0.231
  **Luminal and HER2 subtypes**                                                                
  *PIK3CA* mutation vs wild--type   1.323 (0.752--2.327)   0.332       2.125 (1.032--4.375)    **0.041**
  Exon 20 mutation vs wild-type     1.969 (0.988--3.923)   0.054       2.337 (1.024--5.331)    **0.044**

**Note:** *P*\<0.05 was considered statistically significant and those values are shown in bold.

**Abbreviations:** HER2, human epidermal growth factor receptor 2; PFS, progression-free survival; PR, progesterone receptor; OS, overall survival.

###### 

Comparison of association between *PIK3CA* mutations and various clinicopathological features in different studies

  Authors                                  Year of publication   Country     No. of patients   *PIK3CA* mutation   Sample type   Methods     Association between *PIK3CA* mutations and clinicopathological characteristics
  ---------------------------------------- --------------------- ----------- ----------------- ------------------- ------------- ----------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                                             
  Arsenic et al[@b21-cmar-11-1473]         2014                  Germany     241               15.8%               FTS           DS          H1047R mutation: worse overall survival
  Barbareschi et al[@b24-cmar-11-1473]     2007                  Italy       163               27.6%               FTS           SSCP + DS   Exon 20 mutations: prolonged overall and disease-free survival; exon 9 mutations: poor prognosis for disease-free survival and overall survival
  Bozhanov et al[@b35-cmar-11-1473]        2010                  Bulgaria    145               31.3%               FTS           SSCP + DS   *PIK3CA* mutations: PR positive
  Cizkova et al[@b26-cmar-11-1473]         2012                  France      452               33.4%               FTS           DS          *PIK3CA* mutations: low histopathological grade, small macroscopic tumor size, ER positive, PR positive, HER2 negative, favorable metastasis- free survival
  Kalinsky et al[@b36-cmar-11-1473]        2009                  USA         590               33%                 FFPE          MA + DS     *PIK3CA* mutations: ER positive, PR positive, HER2 negative, low-grade tumor; exon 9 mutations: older age; exon 20 mutations: node negative
  Liang et al[@b37-cmar-11-1473]           2006                  Singapore   80                39%                 FFPE          DS          Exon 20 mutations: older age, early stage
  López-Knowles et al[@b38-cmar-11-1473]   2010                  Australia   168               7%                  FFPE          DS          No significance
  Mangone et al[@b39-cmar-11-1473]         2012                  Brazil      86                27%                 FTS           SSCP + DS   Exon 20 mutations: poor overall survival and disease-free survival
  Maruyama                                 2007                  Japan       188               24.47%              FTS           DS          *PIK3CA* mutations: ER positive, favorable
  et al[@b40-cmar-11-1473]                                                                                                                   prognosis
  Pérez-Tenorio et al[@b41-cmar-11-1473]   2007                  Sweden      270               24%                 FTS           SSCP + DS   *PIK3CA* mutations: ER positive, small tumor size, HER2 negative, longer local recurrence- free survival
  Azizi Tabesh et al[@b42-cmar-11-1473]    2016                  Iran        80                45%                 FTS           DS          *PIK3CA* mutations: low grade; Exon 20 mutations: PR positive
  Current study                            2018                  China       494               38.06%              FFPE          DS          *PIK3CA* mutations: luminal and HER2 positive, ER positive, PR positive, low Ki67 index, better overall survival; exon 9 mutations: worse progressive-free survival; exon 20 mutations: better progressive-free survival and overall survival; H1047 mutations: older age, better progressive-free survival and overall survival; non-hotspot mutations: larger tumor size

**Abbreviations:** DS, direct sequencing; ER, estrogen receptor; FFPE, formalin-fixed, paraffin-embedded tissue samples; FTS, frozen tissue samples; HER2, human epidermal growth factor receptor 2; MA, MassARRAY; PR, progesterone receptor; SSCP, single-strand conformation polymorphism.
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